BACKGROUND: Topoisomerase I is required for DNA relaxation during critical cellular functions. The identification of camptothecins as specific enzyme inhibitors and their clinical efficacy have stimulated extensive efforts to exploit topoisomerase I as a tumor target and explain the putative mechanisms of antitumor-specific action. OBJECTIVE: This review provides an overview of the recent achievements in the development of topoisomerase I inhibitors and in the explanation of the biological pathways involved in tumor response. RESULTS/ CONCLUSION: In spite of the difficulty to identify novel topoisomerase I inhibitors with improved pharmacological properties, a growing body of evidence supports the possibility of optimizing the therapeutic profile of available agents. The explanation of defense mechanisms and the molecular determinants of tumor cell response is expected to provide a basis for the design of combination approaches for optimization of topoisomerase I inhibitors-based therapy.
BACKGROUND: Topoisomerase I is required for DNA relaxation during critical cellular functions. The identification of camptothecins as specific enzyme inhibitors and their clinical efficacy have stimulated extensive efforts to exploit topoisomerase I as a tumor target and explain the putative mechanisms of antitumor-specific action. OBJECTIVE: This review provides an overview of the recent achievements in the development of topoisomerase I inhibitors and in the explanation of the biological pathways involved in tumor response. RESULTS/ CONCLUSION: In spite of the difficulty to identify novel topoisomerase I inhibitors with improved pharmacological properties, a growing body of evidence supports the possibility of optimizing the therapeutic profile of available agents. The explanation of defense mechanisms and the molecular determinants of tumor cell response is expected to provide a basis for the design of combination approaches for optimization of topoisomerase I inhibitors-based therapy.
Authors: Richard E J Forster; Sharon A Small; Yiqing Tang; Clare L Heaysman; Andrew W Lloyd; Wendy Macfarlane; Gary J Phillips; Milan D Antonijevic; Andrew L Lewis Journal: J Mater Sci Mater Med Date: 2010-06-19 Impact factor: 3.896
Authors: D Alan Anthoney; Jay Naik; Iain R J Macpherson; Donna Crawford; John M Hartley; Janet A Hartley; Tomohisa Saito; Masaichi Abe; Keith Jones; Masanori Miwa; Christopher Twelves; T R J Evans Journal: BMC Cancer Date: 2012-11-21 Impact factor: 4.430